The COVID-IDR dashboard provides self-service access to de-identified patient demographic data from the EHR, incorporating HL7’s FHIR standard, and available biospecimens. After using drill-down functionality to select a cohort of interest, the user can:
- Download de-identified data
- Submit a request for identified information using an honest broker (IRB approval required)
- Contact investigators with samples to inquire about sharing process
Participating protocols are described below:
PI: Chris Woods
Contact: chris.woods@duke.edu, susanna.naggie@duke.edu
The aim of this data and specimen repository is to provide a secure and centralized storage location and resource for the collection of core variables of interest, as well as the retaining of relevant patient samples, across COVID-19 related protocols at Duke. The core data variables were in-part selected to specifically match those agreed upon by Academic Medical Centers across the U.S., with the intention of aiding the efficiency and effectiveness of de-identified data reuse for population-level research. This shared data and bio-repository project will house all the core data for all patients with COVID-19 (or suspected cases), as well as individual participants informed consent forms for all other participating COVID-19 studies enrolling Duke patients. Each participating study will have its own separate IRB approved protocol. Specimens consist of residual (left-over) clinical samples from the testing and treatment of patients with COVID-19 at Duke. All specimens were processed in the clinical laboratory and retained for future use. Identifiable data will only be available for consented participants or patients meeting waiver of informed consent; any data for patients who were not approached for consent or do not fall under a waiver will only be shared in a deidentified manner.
PI: Chris Woods
Contact: chris.woods@duke.edu
This observational multi-visit study will enroll up to 4,000 patients presenting to an outpatient clinic, emergency department, hospitalized patients, as well as patients in the community with suspected symptoms of infection, including bacterial, viral, parasitic or tick-borne infection, or with symptoms that mimic infectious illness. Patients may also self-refer to the study. We may also recruit subjects who are exposed to infectious disease from a close contact.
We will collect samples and data from the patient, including blood, nasal swabs, throat swabs, urine and stool. The primary objective is to identify biomarkers for early diagnosis of, or for prognosis of poor outcome in patients with infections. We will collect samples and data from the subject, including blood, nasal swabs, throat swabs, urine and stool. The primary objective is to identify biomarkers for early diagnosis of, or for prognosis of poor outcome in patients with infections.
PI: Matthew Kelly
Contact: matthew.kelly@duke.edu
The purpose of this study is to collect longitudinal biospecimens and clinical information from children, adolescents, and young adults at Duke University Health System (DUHS) practices and/or in the local surrounding community who have been diagnosed with coronavirus disease 2019 (i.e., COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We will primarily recruit patients enrolled in Pro00105249 to this study protocol, but other eligible participants will also be included. This repository will support the development of basic science, translational, and clinical research projects to define mechanisms underlying SARS-CoV-2 disease severity and to examine long-term immune responses to SARS-CoV-2 in a pediatric population.
Study participants will include children, adolescents, and young adults with confirmed or suspected SARS-CoV-2 infection and/or who are known to have had close contact with an individual suspected or confirmed to have SARS-CoV-2 infection. It is anticipated that we will enroll up to 1000 children, adolescents, and young adults in this study. The participants and/or their parent/legal guardian or legal authorized representative will be asked to consent to: 1) a brief caregiver or patient questionnaire assessing the child or adolescent’s past medical history and details of his/her COVID-19 infection/illness course and/or SARS-CoV-2 exposure risk; 2) review of electronic health record data; 3) prospective access to electronic health data for 5 years; and 4) collection of biospecimens, i.e., whole blood, nasal swabs, and saliva at study visits.
PI: Loretta Que
Contact: loretta.que@duke.edu
The primary objective of this project is to develop a comprehensive and extensive repository of biological samples and relevant clinical data from critically ill patients admitted to Duke Hospital with the intent to develop collaboration across Duke and other external institutions. The repository collects biological samples and clinical data from COVID-19 positive patients who have been evaluated at Duke for COVID-19. Collaborators may utilize the biorepository to ascertain relevant clinical data and crucial biological samples, such as, but not limited to, plasma and serum (blood draw), oral/nasopharyngeal swabs, questionnaire data (SF-12, PHQ-9, CAT, CV Resp, modified BORG) and relevant clinical data (via electronic medical record) from COVID-19 positive patients who were seen at Duke Hospital, Duke Regional Hospital or Duke Raleigh Hospital and clinics. The biological samples are collected at 6 weeks, 3 months, 6 months and 12 months post-discharge when patients are seen in pulmonary clinic.
PI: Shannon J. McCall
Contact: shannon.mccall@duke.edu
Autopsy specimens from patients with COVID-19 were acquired under this BRPC protocol. The BRPC, accredited by the College of American Pathologists (CAP), collects and processes high quality biospecimens.